Compare XYL & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XYL | GEHC |
|---|---|---|
| Founded | 2011 | 1892 |
| Country | United States | United States |
| Employees | N/A | 54000 |
| Industry | Fluid Controls | Computer Software: Prepackaged Software |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2B | 27.7B |
| IPO Year | 2011 | 2022 |
| Metric | XYL | GEHC |
|---|---|---|
| Price | $116.58 | $60.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 13 |
| Target Price | ★ $152.50 | $88.38 |
| AVG Volume (30 Days) | 2.3M | ★ 4.7M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.49% | 0.24% |
| EPS Growth | ★ 7.40 | 4.84 |
| EPS | 0.79 | ★ 0.85 |
| Revenue | $9,035,000,000.00 | ★ $20,625,000,000.00 |
| Revenue This Year | $2.79 | $7.12 |
| Revenue Next Year | $4.49 | $4.45 |
| P/E Ratio | $145.52 | ★ $71.71 |
| Revenue Growth | ★ 5.52 | 4.84 |
| 52 Week Low | $114.15 | $58.75 |
| 52 Week High | $154.27 | $89.77 |
| Indicator | XYL | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 29.17 |
| Support Level | N/A | N/A |
| Resistance Level | $141.89 | $75.11 |
| Average True Range (ATR) | 3.03 | 1.95 |
| MACD | -0.69 | -1.11 |
| Stochastic Oscillator | 20.22 | 12.50 |
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $9 billion in revenue in 2025.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).